To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Oncolytics Biotech® Announces Issuance of 35th U.S. Patent for Cellular Proliferative Disorders
Read time: Less than a minute
Oncolytics Biotech Inc. has announced that it has been granted its 35th U.S. Patent, No. 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders."
The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.
"This patent provides further coverage with respect to the use of a range of modified viruses to treat a variety of different cancers," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.
Oncolytics now has issued patents that cover methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus in addition to an extensive patent portfolio covering oncolytic reovirus.
The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.
"This patent provides further coverage with respect to the use of a range of modified viruses to treat a variety of different cancers," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.
Oncolytics now has issued patents that cover methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus in addition to an extensive patent portfolio covering oncolytic reovirus.
